Physician profile
Tyler Waid
NPI 1184207565
$1,278.35
in general payments reported to CMS, 2019-2025
21 companies · $960 in 2025
The $960 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $19.03 · 2024: $299 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $217.68 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $192.68 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $142.99 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Abbvie INC. | $124.34 | 2024-2025 | |
| Exact Sciences Corporation | $105.26 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $80.33 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $60.03 | 2023-2025 | |
| Glaxosmithkline, LLC. | $46.85 | 2025 | Arexvy, Shingrix |
| Shield Therapeutics INC | $33.88 | 2025 | |
| Fisher & Paykel Healthcare INC | $33.71 | 2025 | Fisher & Paykel Healthcare |
| Dexcom, INC. | $27.76 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $27.44 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.95 | 2025 | Jardiance |
| Axsome Therapeutics, INC. | $24.85 | 2025 | Auvelity |
| Dynavax Technologies Corporation | $23.02 | 2025 | Heplisav-B |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $22.91 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.07 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $18.20 | 2025 | |
| Tolmar, INC. | $17.05 | 2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $16.95 | 2024 | Quviviq |
| Hikma Pharmaceuticals USA | $16.40 | 2025 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Waid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.